BLAINJECTIONINJECTABLE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
HYRIMOZ (adalimumab-adaz) by Novartis is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2018.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYRIMOZ (adalimumab-adaz) is a monoclonal antibody that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is indicated for seven chronic inflammatory conditions including rheumatoid arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis. Administered via subcutaneous injection, it suppresses pathological immune responses across multiple autoimmune and inflammatory disorders.
Peak
HYRIMOZ is at peak lifecycle under Novartis ownership with moderate competitive pressure (30/100), suggesting stable commercial operations and mid-sized team infrastructure.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Started Feb 2023
562 enrolled
Inflammatory Bowel Disease
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Started Jun 2019
63 enrolled
Crohn´s Disease
Career Relevance
Working on HYRIMOZ offers exposure to mature-market brand management within a highly competitive TNF-inhibitor and immunosuppressant space under Novartis ownership. Career development is concentrated in commercial execution, managed care negotiation, and field-based sales rather than innovation or clinical advancement.
Worked on HYRIMOZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.